Clinical Trial Update: Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab in combination with pegylated liposomal doxorubicin for recurrent platinum-resistant ovarian, fallopian tube, or perito…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-08-03